Phase 1 Alzheimer's Disease Trial, Recruiting NCT05231785 Sponsor: Alnylam Pharmaceuticals Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 1 Alzheimer's Disease Trial, Recruiting

NCT05231785
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with mild memory or thinking problems, or mild dementia, caused by early-onset Alzheimer's disease.
  • Your memory and thinking abilities, as measured by standard medical tests, fall within a specific mild range (confirm with trial site).

Who may not be able to join:

  • Your dementia is caused by something other than Alzheimer's disease.
  • Your liver is not functioning within a normal healthy range, based on a blood test (confirm with trial site).
  • Your kidneys are not filtering blood well enough, based on a blood test (confirm with trial site).
  • You have recently taken part in another clinical trial and received an experimental treatment.
  • You have recently been treated with a medication that targets amyloid, a protein linked to Alzheimer's disease (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Please note: Additional eligibility requirements not listed here may also apply, as stated by the trial organisers. Always check the full criteria with the trial team.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Director, Alnylam Pharmaceuticals

Phone: 1-877-ALNYLAM

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Alnylam Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
4 February 2022
Est. completion
20 April 2029

Where this trial is recruiting

🇨🇦 Canada 🇳🇱 Netherlands 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Part A: Frequency of Adverse Events; Part B: Frequency of Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov